CMS aims to tackle drug costs by giving payers more bargaining power
If a drug manufacturer raises the price of a protected drug beyond a certain threshold it risks being excluded from payers’ formularies, according to the proposed rule. Payers could also exclude a protected class drug that is not a significant innovation over the original product, Verma said Monday.
